

Communicable Disease Market: A BCC Research Overview

<https://marketpublishers.com/r/CAD88F5FD99EN.html>

Date: July 2019

Pages: 151

Price: US\$ 2,750.00 (Single User License)

ID: CAD88F5FD99EN

Abstracts

REPORT SCOPE:

The scope of this report is broad and covers therapeutics used in treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.

The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

REPORT INCLUDES:

23 data tables and 24 additional tables

Detailed overview of the global market for communicable diseases within the

healthcare industry

Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024

Regional analysis of the communicable disease market, covering North America, Europe, Asia-Pacific, South America and Middle East & Africa

A look at the government regulations pertaining to drug developments for communicable diseases and pipeline analysis covering ongoing clinical trials and promising forthcoming therapies in late stage

Discussion of competitive landscape, mergers and acquisitions of companies to enhance their product portfolio, and future commercial marketplace

Comprehensive company profiles of major market players, including Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, Novartis AG and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Disease Overview
HIV
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Epidemiology
Chlamydia
Epidemiology
Genital Herpes
Epidemiology
Gonorrhea
Epidemiology
Hepatitis A, B and C
Epidemiology
HPV
Syphilis
Epidemiology
Malaria
Incidence and Geographical Distribution
Tuberculosis
Incidence and Geographical Distribution

Influenza
Incidence and Mortality
Trichomoniasis
Scabies
Bacterial Vaginosis
Candidiasis
Chancroid (Venereal Ulcers)
Pediculosis Pubis

CHAPTER 4 MARKET DYNAMICS

Market Drivers
Regional Awareness Program for Communicable Diseases
Development of Novel Therapies
Public Private Partnership
Global Program to Counter HIV
Increasing Prevalence of Communicable Diseases
Market Restraints
Social Stigma Associated with STD
High Cost of Treatment
Underestimating the Risk of Contracting the Disease
Lack of Prenatal Screenings for STD

CHAPTER 5 MARKET BREAKDOWN BY DISEASE TYPE

Global Market for Communicable Disease, by Disease Indication
HIV
Market Size and Forecast
Market Analysis
Hepatitis B&C
Market Size and Forecast
Market Analysis
Herpes Simplex Virus
Market Size and Forecast
Market Analysis
Influenza
Market Size and Forecast
Market Analysis
Malaria

Market Size and Forecast
Market Analysis
Tuberculosis
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis

CHAPTER 6 MARKET BREAKDOWN BY REGION

Global Market for Communicable Disease, by Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Middle East & Africa

CHAPTER 7 PIPELINE ANALYSIS

Overview
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza A and Influenza B
Respiratory Syncytial Virus

Malaria
Tuberculosis
MERS
Hemorrhagic Fevers
Dengue
Ebola
Lassa fever
Marburg
Yellow Fever
Zika

CHAPTER 8 REGULATION AND REIMBURSEMENT

Regulations
U.S.
Europe
Japan
China
Pricing and Reimbursement
U.S.
Europe
Japan

CHAPTER 9 COMPETITIVE LANDSCAPE

Sexually Transmitted Disease Therapeutics: Global Competitor Analysis
Influenza Therapeutics: Global Competitor Analysis

CHAPTER 10 COMPANY PROFILES

ABBOTT LABORATORIES
ABBVIE INC.
ASTRAZENECA/MEDIMMUNE
AUROBINDO PHARMA LTD.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
BRISTOL-MYERS SQUIBB CO.
CIPLA INC.
DAIICHI SANKYO
GILEAD SCIENCES, INC.

GLAXOSMITHKLINE PLC
JANSSEN PHARMACEUTICALS, INC.
MERCK & CO., INC.
MITSUBISHI TANABE PHARMA CORP.
MYLAN LABORATORIES
NOVARTIS AG
PFIZER INC.
HOFFMANN-LA ROCHE INC.
SANOFI, SANOFI PASTEUR
SEQIRUS, A CSL COMPANY
VIIV HEALTHCARE

CHAPTER 11 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table: Global Communicable Disease Market, by Region, Through 2024

Table 1: Milestones in the History of HIV

Table 2: Life Cycle of HIV Therapeutics Target Points

Table 3: HIV Incidence, by Country, 2005-2016

Table 4: HIV Incidence, by Country, 2014-2017

Table 5: Chlamydia Incidence, by Country, 2012-2017

Table 6: Global HSV-1 Prevalence Aged 0-49 years, by Region, 2012

Table 7: Gonorrhoea Epidemiology, by Country, 2012-2017

Table 8: Hepatitis A Incidence, by Country, 2012-2017

Table 9: Hepatitis B Incidence, by Country, 2012-2017

Table 10: Hepatitis C Incidence, by Country, 2012-2015

Table 11: Syphilis Incidence, by Country, 2013-2016

Table 12: Infectious Syphilis Incidence, by Country, 2012-2014

Table 13: Suspected Malaria Cases, by WHO Region, 2010-2015

Table 14: Confirmed Malaria Cases, by WHO Region, 2010-2015

Table 15: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010

Table 16: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type and Manufacturer

Table 17: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer

Table 18: Global Communicable Disease Market, by Disease Indication, Through 2024

Table 19: Global HIV Therapeutics Market, by Drug Class, Through 2024

Table 20: ART Therapy Coverage, by Region, 2017

Table 21: North American Estimated HBsAG Seroprevalence, 2016

Table 22: Drug for Chlamydia Treatment

Table 23: Drug for Gonorrhoea Treatment

Table 24: Global Communicable Disease Market, by Region, Through 2024

Table 25: North American Communicable Disease Market, by Country, Through 2024

Table 26: European Communicable Disease Market, by Country/Region, Through 2024

Table 27: Asia-Pacific Communicable Disease Market, by Country/Region, Through 2024

Table 28: South American Estimated HBsAG Seroprevalence, by Country, 2016

Table 29: Hepatitis B and Hepatitis C Development Pipeline and Recent Launches, 2019

Table 30: Herpes Simplex Virus Development Pipeline and Recent Launches, 2019

Table 31: HIV/AIDS Development Pipeline and Recent Launches, 2019

Table 32: Influenza A and Influenza B Development Pipeline and Recent Launches, 2019

Table 33: RSV Development Pipeline and Recent Launches, 2019

Table 34: Malaria Development Pipeline and Recent Launches, 2019

Table 35: Tuberculosis Development Pipeline and Recent Launches, 2019

Table 36: MERS Development Pipeline and Recent Launches, 2019

Table 37: Dengue Development Pipeline and Recent Launches, 2019

Table 38: Ebola Development Pipeline and Recent Launches, 2019

Table 39: Lassa Fever Development Pipeline and Recent Launches, 2019

Table 40: Marburg Development Pipeline and Recent Launches, 2019

Table 41: Yellow Fever Development Pipeline and Recent Launches, 2019

Table 42: Zika Development Pipeline and Recent Launches, 2019

Table 43: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing

Table 44: Preventive Health Services for Children Covered by Private Plans without Cost Sharing

Table 45: Global Market Share Analysis for Sexually Transmitted Disease Therapeutics, by Company, 2019

Table 46: Acronyms Used in This Report

List Of Figures

LIST OF FIGURES

- Summary Figure: Global Communicable Disease Market Share, by Region, 2018
- Figure 1: Types of Drug Failure Encountered During HIV Treatment
- Figure 2: Global Historic and Current HIV Prevalence Trend, 2012-2016
- Figure 3: Estimated HIV Regional Prevalence, 2016
- Figure 4: Estimated HIV Regional Incidence, 2016
- Figure 5: Global Historic and Current Chlamydia Incidence Women Trend, 2012-2014
- Figure 6: Global Historic and Current Chlamydia Incidence Men Trend, 2012-2014
- Figure 7: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
- Figure 8: Global Historic and Current Gonorrhea Incidence Women Trend, 2012-2014
- Figure 9: Hepatitis Timeline, 1990-2004
- Figure 10: Hepatitis Timeline, 2011-2015
- Figure 11: Hepatitis Timeline, 2015-2017
- Figure 12: U.S. Syphilis Incidence Among Newborns, 2014-2016
- Figure 13: Global Historic and Current Infectious Syphilis Incidence Men Trend, 2012-2014
- Figure 14: Global Prevalence of Tuberculosis, 1990-2015
- Figure 15: Global Incidence of Tuberculosis, 1990-2015
- Figure 16: U.S. Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017
- Figure 17: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016
- Figure 18: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
- Figure 19: Global Communicable Disease Market, by Disease Indication, 2018-2024
- Figure 20: Global HIV Market, 2018-2024
- Figure 21: Global Prevalence of HIV, by Region, 2016
- Figure 22: Global Incidence of HIV, by Region, 2016
- Figure 23: Global Hepatitis Market, 2018-2024
- Figure 24: Global Herpes Simplex Virus Market, 2018-2024
- Figure 25: Global Market for HSV Therapeutics, by WHO Region, 2016-2022
- Figure 26: Global Influenza Market, 2018-2024
- Figure 27: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017
- Figure 28: Global Malaria Market, 2018-2024
- Figure 29: Global Tuberculosis Market, 2018-2024
- Figure 30: Global Others Market, 2018-2024
- Figure 31: Global Communicable Disease Market Share, by Region, 2018
- Figure 32: North American Communicable Disease Market, 2018-2024
- Figure 33: North American Communicable Disease Market Share, by Country, 2018

Figure 34: U.S. Communicable Disease Market, 2018-2024

Figure 35: Canadian Communicable Disease Market, 2018-2024

Figure 36: Mexican Communicable Disease Market, 2018-2024

Figure 37: European Communicable Disease Market Share, by Country/Region, 2018

Figure 38: German Communicable Disease Market, 2018-2024

Figure 39: French Communicable Disease Market, 2018-2024

Figure 40: French Historic and Current Chlamydia Incidence Trend, 2011-2015

Figure 41: French Historic and Current Gonorrhoea Incidence Trend, 2011-2015

Figure 42: U.K. Communicable Disease Market, 2018-2024

Figure 43: Spanish Communicable Disease Market, 2018-2024

Figure 44: Italian Communicable Disease Market, 2018-2024

Figure 45: Rest of European Communicable Disease Market, 2018-2024

Figure 46: Asia-Pacific Communicable Disease Market Share, by Country/Region, 2018

Figure 47: Japanese Communicable Disease Market, 2018-2024

Figure 48: Japanese Historic and Current HIV/AIDS Infections Incidence, 2001-2016

Figure 49: Chinese Communicable Disease Market, 2018-2024

Figure 50: Indian Communicable Disease Market, 2018-2024

Figure 51: Rest of Asia-Pacific Communicable Disease Market, 2018-2024

Figure 52: South American Communicable Disease Market, 2018-2024

Figure 53: Middle East and African Communicable Disease Market, 2018-2024

Figure 54: Global Influenza Therapeutics Market Share, by Manufacturer, 2018

Figure 55: Global Competitor Market Analysis for Influenza Therapeutics, 2018

I would like to order

Product name: Communicable Disease Market: A BCC Research Overview

Product link: <https://marketpublishers.com/r/CAD88F5FD99EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAD88F5FD99EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970